While GBM remains a devastating disease, GRP78-based therapies may hold significant promise in prolonging overall survival, delaying tumor progression, and decreasing treatment resistance and recurrence in GBM, ultimately providing hope that future treatments might convert GBM from a malignant disease to a chronic one. This evidence concerns the gene HSPA5 and glioblastoma.